Rule S - Search Results

1

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.

Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. Rule S, et al. Haematologica. 2016 Feb;101(2):235-40. doi: 10.3324/haematol.2015.128710. Epub 2015 Nov 26. Haematologica. 2016. PMID: 26611473 Free PMC article. Clinical Trial.

2

Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.

Thomas DW, Owen RG, Johnson SA, Hillmen P, Seymour JF, Wolf MM, Rule SA. Thomas DW, et al. Leuk Lymphoma. 2005 Apr;46(4):549-52. doi: 10.1080/10428190400029841. Leuk Lymphoma. 2005. PMID: 16019483

3

Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.

Eve HE, Linch D, Qian W, Ross M, Seymour JF, Smith P, Stevens L, Rule SA. Eve HE, et al. Leuk Lymphoma. 2009 Feb;50(2):211-5. doi: 10.1080/10428190802688509. Leuk Lymphoma. 2009. PMID: 19197729 Clinical Trial.

4

Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.

Eve HE, Seymour JF, Rule SA. Eve HE, et al. Leuk Lymphoma. 2009 Mar;50(3):463-5. doi: 10.1080/10428190802641979. Leuk Lymphoma. 2009. PMID: 19197732 Clinical Trial. No abstract available.

5

How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?

Shah N, Tam C, Seymour JF, Rule S. Shah N, et al. Among authors: rule s. Leuk Lymphoma. 2015 Jun;56(6):1599-610. doi: 10.3109/10428194.2014.963083. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25213181 Review.

6

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Tucker DL, Naylor G, Kruger A, Hamilton MS, Follows G, Rule SA. Tucker DL, et al. Among authors: rule sa. Br J Haematol. 2017 Jul;178(2):327-329. doi: 10.1111/bjh.14122. Epub 2016 May 16. Br J Haematol. 2017. PMID: 27197509 Free article. No abstract available.

7

Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.

McCulloch R, Lewis D, Crosbie N, Eyre TA, Bolam S, Arasaretnam A, Creasey T, Goradia H, McMillan A, Dawi S, Harrison S, Miles O, Robinson A, Dutton D, Wilson MR, McKay P, Follows G, Phillips N, Patmore R, Lambert J, Bishton M, Osborne W, Johnston R, Kirkwood AA, Rule S. McCulloch R, et al. Among authors: rule s. Br J Haematol. 2021 Apr;193(2):290-298. doi: 10.1111/bjh.17363. Epub 2021 Feb 23. Br J Haematol. 2021. PMID: 33620106 Free article.

8

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.

9

Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.

Furtado M, Johnson R, Kruger A, Turner D, Rule S. Furtado M, et al. Among authors: rule s. Br J Haematol. 2015 Jan;168(1):55-62. doi: 10.1111/bjh.13101. Epub 2014 Aug 22. Br J Haematol. 2015. PMID: 25146720 Free article. Clinical Trial.

10

Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.

Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, Sureda A, Patrick P, Clifton-Hadley L, Adedayo T, Kirkwood A, Peggs KS. Rule S, et al. Br J Haematol. 2019 Mar;184(6):999-1005. doi: 10.1111/bjh.15723. Epub 2018 Dec 17. Br J Haematol. 2019. PMID: 30560573 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page